- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04115397
Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints (PREVENT RA)
Towards Efficient Prediction and Prevention of Rheumatoid Arthritis
Seropositive Rheumatoid arthritis (RA) is characterized by autoantibodies that develop prior to clinical onset, allowing identification of individuals at risk for disease development. In a unique program in Stockholm, seropositive individuals presenting with musculoskeletal complains are currently identified and followed-up in a dedicated outpatient clinical program. Despite significant disease burden and increased sick leave among these individuals, we lack today any therapeutic and preventive measures.
We aim to (1). establish a nation-wide health program, (2). develop an algorithm for disease risk estimation and (3). test a novel strategy to delay and/or prevent disease onset in seropositive at risk individuals with musculoskeletal complains. We will perform a multicentre randomised study to treat autoantibody-positive individuals at risk for developing RA presenting with pain (Population), by repurposing of bisphosphonates (Intervention) as compared to placebo (Control) to treat pain (primary Outcome) and delay/prevent RA development during 1-year follow-up (secondary Outcome)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
we have recently identified a novel disease-triggering pathogenic mechanism in autoantibody-positive individuals consisting in a bone-mediated induction of pain by autoantibodies. We hypothesize that specific targeting of this new mechanism, rather than using therapies developed for already established disease (where other mechanisms are active), will be able to treat pain with arthralgia and halt disease progression in seropositive at-risk individuals.
We will address this hypothesis by repurposing of bisphosphonates, currently used in clinical practice in both RA patients as well as in many individuals at risk for RA (mainly women in post-menopausal age). We will perform a multi centre, prospective, randomised, double-blind and placebo-controlled study with 2 parallel groups.
Patients will be randomised 1:1 to receive either one infusion aclasta (5 mg zolendronic acid, n=40) or placebo (n=40). The primary outcome is the VAS pain score and the study is powered to detect a 20% difference in the primary endpoint between the active and the control arm. The study is powered to detect a 20-percentage point difference in proportions between the control and the treated group. Subjects may withdraw from the trial at any time at their own or the investigators request for safety reasons.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age older than 18 years Lack of arthritis as estimated by clinical and ultrasound examination of the joints ACPA positive Intermediate or high risk for RA (according to the algorithm described above) VAS score of at least 20 mm
Exclusion Criteria:
A previous diagnosis of arthritis Intolerance/contraindication to any of the study medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bisphophonate
Zolendronic acid, one infusion iv
|
Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
|
Placebo Comparator: Placebo
Placebo, one infusion iv
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS pain
Time Frame: 3 months
|
PAin on a visual analogue scale
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAQ
Time Frame: 3 months
|
Health assessment questionnaire
|
3 months
|
MRI
Time Frame: 6 months
|
MRI investigation of the symptomatic joints in the hands
|
6 months
|
Rheumatoid Arthritis (RA ) diagnosis
Time Frame: 1 year
|
Getting a diagnosis of RA
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/682-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seropositive Muskuloskeletal Complaints
-
Kangbuk Samsung HospitalHanyang University; Soon Chun Hyang University; Kyunghee UniversityUnknownIntestine; Complaints
-
Hillel Yaffe Medical CenterUnknownGastrointestinal ComplaintsIsrael
-
National Cheng Kung UniversityChang Gung University of Science and TechnologySuspendedSubjective Cognitive ComplaintsTaiwan
-
Ewha Womans UniversityCompletedSubjective Memory ComplaintsKorea, Republic of
-
General Hospital GroeningeUniversitair Ziekenhuis Brussel; AZ KlinaCompletedCancer | Subjective Cognitive ComplaintsBelgium
-
Chelsea and Westminster NHS Foundation TrustImperial College London; University of WestminsterCompletedMindfulness | Subjective Cognitive ComplaintsUnited Kingdom
-
Ewha Womans UniversityCompletedHealthy Adults With Subjective Sleep ComplaintsKorea, Republic of
-
Centre Francois BaclesseCompletedCancer | Metamemory | Memory Complaints | Performance MnemonicFrance
-
Ewha Womans UniversityCompletedHealthy Adults With Subjective Memory ComplaintsKorea, Republic of
-
Ewha Womans UniversityCompletedHealthy Adults With Subjective Memory ComplaintsKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States